Bahamontes-Rosa Noemí, Alejandre Ane Rodriguez, Gomez Vanesa, Viera Sara, Gomez-Lorenzo María G, Sanz-Alonso Laura María, Mendoza-Losana Alfonso
Diseases of the Developing World, GlaxoSmithKline, Tres Cantos, 28760, Madrid, Spain.
Malar J. 2016 Mar 8;15:147. doi: 10.1186/s12936-016-1205-x.
Quantitative real-time PCR (qPCR) is now commonly used as a method to confirm diagnosis of malaria and to differentiate recrudescence from re-infection, especially in clinical trials and in reference laboratories where precise quantification is critical. Although anti-malarial drug discovery is based on in vivo murine efficacy models, use of molecular analysis has been limited. The aim of this study was to develop qPCR as a valid methodology to support pre-clinical anti-malarial models by using filter papers to maintain material for qPCR and to compare this with traditional methods.
FTA technology (Whatman) is a rapid and safe method for extracting nucleic acids from blood. Peripheral blood samples from mice infected with Plasmodium berghei, P. yoelii, or P. falciparum were kept as frozen samples or as spots on FTA cards. The extracted genetic material from both types of samples was assessed for quantification by qPCR using sets of specific primers specifically designed for Plasmodium 18S rRNA, LDH, and CytB genes.
The optimal conditions for nucleic acid extraction from FTA cards and qPCR amplification were set up, and were confirmed to be suitable for parasite quantification using DNA as template after storage at room temperature for as long as 26 months in the case of P. berghei samples and 52 months for P. falciparum and P. yoelii. The quality of DNA extracted from the FTA cards for gene sequencing and microsatellite amplification was also assessed.
This is the first study to report the suitability of FTA cards and qPCR assay to quantify parasite load in samples from in vivo efficacy models to support the drug discovery process.
定量实时聚合酶链反应(qPCR)现在通常用作确诊疟疾以及区分复发与再感染的方法,特别是在临床试验和精确量化至关重要的参考实验室中。尽管抗疟药物研发基于体内小鼠疗效模型,但分子分析的应用一直有限。本研究的目的是开发qPCR作为一种有效的方法,通过使用滤纸保存用于qPCR的材料来支持临床前抗疟模型,并将其与传统方法进行比较。
FTA技术(Whatman公司)是一种从血液中提取核酸的快速且安全的方法。感染伯氏疟原虫、约氏疟原虫或恶性疟原虫的小鼠外周血样本保存为冷冻样本或FTA卡上的斑点。使用专门为疟原虫18S rRNA、乳酸脱氢酶(LDH)和细胞色素B(CytB)基因设计的特异性引物组,通过qPCR对两种类型样本中提取的遗传物质进行定量评估。
建立了从FTA卡提取核酸和qPCR扩增的最佳条件,并证实适用于以DNA为模板的寄生虫定量,伯氏疟原虫样本在室温下保存长达26个月,恶性疟原虫和约氏疟原虫样本保存52个月后仍适用。还评估了从FTA卡提取的用于基因测序和微卫星扩增的DNA质量。
这是第一项报告FTA卡和qPCR检测适用于定量体内疗效模型样本中的寄生虫载量以支持药物研发过程的研究。